Misotac vs Combined Oral Contraceptive Pill in the Treatment of Symptomatic Isthmocele
Status:
Not yet recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Isthmocele is a growing concern as a cause of abnormal uterine bleeding, especially post
menstrual bleeding which may be present in up to 82% of these cases (Iannone et al 2019).
our trial is a randomized clinical trial in which women will be randomly allocated to either
medical treatment by oral contraceptive or to medical treatment by misotac.